Abstract:BACKGROUND:Neuroinflammation is characterized by microglial activation and the increased levels of cytokines and chemokines in the central nervous system (CNS). Recent evidence has implicated both beneficial and toxic roles of microglia when over-activated upon nerve injury or in neurodegenerative diseases, including Alzheimer's disease (AD). The low-density lipoprotein receptor-related protein 1 (LRP1) is a major receptor for apolipoprotein E (apoE) and amyloid-β (Aβ), which play critical roles in AD pathogenesis. LRP1 regulates inflammatory responses in peripheral tissues by modulating the release of inflammatory cytokines and phagocytosis. However, the roles of LRP1 in brain innate immunity and neuroinflammation remain unclear.METHODS:In this study, we determined whether LRP1 modulates microglial activation by knocking down Lrp1 in mouse primary microglia. LRP1-related functions in microglia were also assessed in the presence of LRP1 antagonist, the receptor-associated protein (RAP). The effects on the production of inflammatory cytokines were measured by quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). Potential involvement of specific signaling pathways in LRP1-regulated functions including mitogen-activated protein kinases (MAPKs) and nuclear factor-κB (NF-κB) were assessed using specific inhibitors.RESULTS:We found that knocking down of Lrp1 in mouse primary microglia led to the activation of both c-Jun N-terminal kinase (JNK) and NF-κB pathways with corresponding enhanced sensitivity to lipopolysaccharide (LPS) in the production of pro-inflammatory cytokines. Similar effects were observed when microglia were treated with LRP1 antagonist RAP. In addition, treatment with pro-inflammatory stimuli suppressed Lrp1 expression in microglia. Interestingly, NF-κB inhibitor not only suppressed the production of cytokines induced by the knockdown of Lrp1 but also restored the down-regulated expression of Lrp1 by LPS.CONCLUSIONS:Our study uncovers that LRP1 suppresses microglial activation by modulating JNK and NF-κB signaling pathways. Given that dysregulation of LRP1 has been associated with AD pathogenesis, our work reveals a critical regulatory mechanism of microglial activation by LRP1 that could be associated with other AD-related pathways thus further nominating LRP1 as a potential disease-modifying target for the treatment of AD.

IRF3 regulates neuroinflammatory responses and the expression of genes associated with Alzheimer's disease

IRF3 regulates neuroinflammatory responses and the expression of genes associated with Alzheimer’s disease

Interferon Regulatory Factor 5 Regulates the Phagocytosis of Microglia and Alleviate Alzheimer's Pathology.

The NLRP3 Inflammasome is Involved in Resident Intruder Paradigm-Induced Aggressive Behaviors in Mice

Interferon Regulatory Factor 5 Mediates Lipopolysaccharide-Induced Neuroinflammation

Expression of Immune Related Genes and Possible Regulatory Mechanisms in Alzheimer's Disease

Expression of Immune Related Genes and Possible Regulatory Mechanisms in Alzheimer’s Disease

TLR4/Rac1/NLRP3 Pathway Mediates Amyloid-β-Induced Neuroinflammation in Alzheimer's Disease

The PHD3-FOXO3 axis modulates the interferon type I response in microglia aggravating Alzheimer's disease progression

NLRC3 Delays the Progression of AD in APP/PS1 Mice Via Inhibiting PI3K Activation

IRF3 inhibits inflammatory signaling pathways in macrophages to prevent viral pathogenesis

IRF3 inhibits nuclear translocation of NF-κB to prevent viral inflammation

The innate immunity protein IFITM3 modulates -secretase in Alzheimer's disease

Reduced SH3RF3 may protect against Alzheimer disease by lowering microglial pro-inflammatory responses via modulation of JNK and NFkB signaling

Microglial responses to peripheral type 1 interferon

The role of interferon signaling in neurodegeneration and neuropsychiatric disorders

Targeting NLRP3 inflammasome for neurodegenerative disorders

Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid plaques

LRP1 Modulates the Microglial Immune Response Via Regulation of JNK and NF-κB Signaling Pathways

Silencing of LRP1 Exacerbates Inflammatory Response Via TLR4/NF-κB/MAPKs Signaling Pathways in APP/PS1 Transgenic Mice

Concerted Cellular Responses to Type I Interferon Propel Memory Impairment Associated with Amyloid Β Plaques